

# Gabriela Riemekasten

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4984090/publications.pdf>

Version: 2024-02-01

114  
papers

12,326  
citations

76196

40  
h-index

26548

107  
g-index

119  
all docs

119  
docs citations

119  
times ranked

10029  
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.5	1,705
3	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1809-1815.	0.5	1,017
4	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794
5	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. <i>Lancet, The</i> , 2016, 387, 2630-2640.	6.3	505
6	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.5	410
7	Mechanisms of Autoantibody-Induced Pathology. <i>Frontiers in Immunology</i> , 2017, 8, 603.	2.2	377
8	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 963-974.	5.2	348
9	Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1355-1360.	0.5	275
10	Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 530-536.	0.5	254
11	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 212-220.	0.5	236
12	Intravenous Injection of a D1 Protein of the Smith Proteins Postpones Murine Lupus and Induces Type 1 Regulatory T Cells. <i>Journal of Immunology</i> , 2004, 173, 5835-5842.	0.4	220
13	Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells. <i>European Journal of Immunology</i> , 2001, 31, 2726-2732.	1.6	214
14	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	2.6	182
15	Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 808-817.	2.5	170
16	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 219-227.	0.5	160
17	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.5	132
18	Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. <i>Arthritis Research and Therapy</i> , 2014, 16, R29.	1.6	125

#	ARTICLE	IF	CITATIONS
19	Angiotensin II Type 1 Receptor Antibodies and Increased Angiotensin II Sensitivity in Pregnant Rats. Hypertension, 2011, 58, 77-84.	1.3	121
20	An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. Rheumatology, 2016, 55, 883-890.	0.9	121
21	GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. Nature Communications, 2018, 9, 5224.	5.8	116
22	Digital ulcers predict a worse disease course in patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 681-686.	0.5	111
23	Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Annals of the Rheumatic Diseases, 2017, 76, 422-426.	0.5	108
24	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 2017, 76, 1207-1218.	0.5	107
25	Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Research and Therapy, 2014, 16, R65.	1.6	93
26	Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 730-737.	0.5	82
27	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 163-169.	0.5	82
28	Transethnic meta-analysis identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1150-1158.	0.5	77
29	Pathogenetic and Clinical Aspects of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitides. Frontiers in Immunology, 2018, 9, 680.	2.2	76
30	Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nature Communications, 2022, 13, 1220.	5.8	74
31	Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases. Nature Reviews Rheumatology, 2017, 13, 648-656.	3.5	73
32	Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis. Autoimmunity Reviews, 2016, 15, 690-694.	2.5	64
33	Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. Annals of the Rheumatic Diseases, 2014, 73, 277-283.	0.5	60
34	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Annals of the Rheumatic Diseases, 2016, 75, 1285-1292.	0.5	56
35	Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. European Respiratory Journal, 2014, 43, 1530-1532.	3.1	54
36	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 2018, 57, 370-381.	0.9	53

#	ARTICLE	IF	CITATIONS
37	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.5	50
38	Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. <i>Rheumatology</i> , 2017, 56, 1618-1626.	0.9	49
39	The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers. <i>Arthritis Research and Therapy</i> , 2015, 17, 94.	1.6	48
40	Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 1801-1807.	1.0	46
41	Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2018, 20, 52.	1.6	44
42	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. <i>Autoimmunity Reviews</i> , 2020, 19, 102452.	2.5	43
43	Influence of <i>TYK2</i> in systemic sclerosis susceptibility: a new <i>locus</i> in the IL-12 pathway. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1521-1526.	0.5	41
44	Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 3675.	1.0	38
45	Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. <i>Nutrition</i> , 2018, 55-56, 51-55.	1.1	37
46	Functional Autoantibodies in Systemic Sclerosis Pathogenesis. <i>Current Rheumatology Reports</i> , 2015, 17, 34.	2.1	36
47	Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: What functional autoimmunity could learn from receptor biology. <i>Arthritis and Rheumatism</i> , 2009, 60, 907-911.	6.7	35
48	CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease. <i>Rheumatology</i> , 2019, 58, 511-521.	0.9	35
49	Environmental factor and inflammation-driven alteration of the total peripheral T-cell compartment in granulomatosis with polyangiitis. <i>Journal of Autoimmunity</i> , 2017, 78, 79-91.	3.0	34
50	What Makes Antibodies Against G Protein-Coupled Receptors so Special? A Novel Concept to Understand Chronic Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 564526.	2.2	34
51	Strong acceleration of murine lupus by injection of the SmD183-119 peptide. <i>Arthritis and Rheumatism</i> , 2001, 44, 2435-2445.	6.7	30
52	Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis. <i>PLoS ONE</i> , 2016, 11, e0153101.	1.1	30
53	Dysregulated homeostasis of target tissues or autoantigens - A novel principle in autoimmunity. <i>Autoimmunity Reviews</i> , 2017, 16, 602-611.	2.5	27
54	Human CD40 ligand deficiency dysregulates the macrophage transcriptome causing functional defects that are improved by exogenous IFN- $\beta$ . <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 900-912.e7.	1.5	27

#	ARTICLE	IF	CITATIONS
55	Mapping urinary chemokines in human lupus nephritis: Potentially redundant pathways recruit CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells and macrophages. <i>European Journal of Immunology</i> , 2017, 47, 180-192.	1.6	26
56	IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4 <sup>+</sup> T Cells in Murine Lupus Nephritis. <i>Cells</i> , 2019, 8, 1234.	1.8	26
57	Nuclear antigen-reactive CD4 <sup>+</sup> T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys. <i>Kidney International</i> , 2021, 99, 238-246.	2.6	26
58	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. <i>Rheumatology</i> , 2015, 54, 1262-1269.	0.9	25
59	Recent advances in mouse models for systemic sclerosis. <i>Autoimmunity Reviews</i> , 2018, 17, 1225-1234.	2.5	24
60	Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ Complication. <i>Journal of Rheumatology</i> , 2020, 47, 241-248.	1.0	24
61	Functional autoantibodies in systemic sclerosis. <i>Seminars in Immunopathology</i> , 2015, 37, 529-542.	2.8	23
62	Autoantibodies against muscarinic acetylcholine receptor M sub 3 sub in Sjogren rsquo s syndrome and corresponding mouse models. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 2053-2064.	3.0	23
63	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101707.	1.4	22
64	CD40 ligand deficiency causes functional defects of peripheral neutrophils that are improved by exogenous IFN- $\beta$ . <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1571-1588.e9.	1.5	21
65	Evaluation of retinal microvascular perfusion in systemic sclerosis: a case-control study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 857-858.	0.5	20
66	In situ detection of PR3-ANCA <sup>+</sup> B cells and alterations in the variable region of immunoglobulin genes support a role of inflamed tissue in the emergence of auto-reactivity in granulomatosis with polyangiitis. <i>Journal of Autoimmunity</i> , 2018, 93, 89-103.	3.0	19
67	The Effects of Antigen-Specific IgG1 Antibody for the Pulmonary-Hypertension-Phenotype and B Cells for Inflammation in Mice Exposed to Antigen and Fine Particles from Air Pollution. <i>PLoS ONE</i> , 2015, 10, e0129910.	1.1	19
68	Monocytic Angiotensin and Endothelin Receptor Imbalance Modulate Secretion of the Profibrotic Chemokine Ligand 18. <i>Journal of Rheumatology</i> , 2016, 43, 587-591.	1.0	17
69	Novelties in the field of autoimmunity - 1st Saint Petersburg congress of autoimmunity, the bridge between east and west. <i>Autoimmunity Reviews</i> , 2017, 16, 1175-1184.	2.5	17
70	Transfer of PBMC From SSc Patients Induces Autoantibodies and Systemic Inflammation in Rag2 <sup>-/-</sup> /IL2rg <sup>-/-</sup> Mice. <i>Frontiers in Immunology</i> , 2021, 12, 677970.	2.2	17
71	Casein is an Essential Cofactor in Autoantibody Reactivity Directed against the C-Terminal SmD1 Peptide AA 83-119 in Systemic Lupus Erythematosus. <i>Immunobiology</i> , 2002, 206, 537-545.	0.8	15
72	Unmasking of autoreactive CD4 T cells by depletion of CD25 regulatory T cells in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2176-2183.	0.5	15

#	ARTICLE	IF	CITATIONS
73	Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 929-939.	1.2	15
74	IgG stimulated $\beta_2$ adrenergic receptor activation is attenuated in patients with ME/CFS. <i>Brain, Behavior, &amp; Immunity - Health</i> , 2020, 3, 100047.	1.3	15
75	Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1281-1289.	0.5	15
76	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 152-157.	0.9	13
77	Autoantibodies in Serum of Systemic Scleroderma Patients: Peptide-Based Epitope Mapping Indicates Increased Binding to Cytoplasmic Domains of CXCR3. <i>Frontiers in Immunology</i> , 2018, 9, 428.	2.2	13
78	Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 115-135.	1.3	12
79	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 626-628.	0.5	12
80	Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. <i>Archives of Rheumatology</i> , 2019, 34, 253-261.	0.3	12
81	Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis. <i>Scientific Reports</i> , 2020, 10, 15931.	1.6	11
82	Lowered anti- $\beta_1$ adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome. <i>Scientific Reports</i> , 2019, 9, 14552.	1.6	10
83	Low-dose IL-2 therapy "a complex scenario that remains to be further explored. <i>Nature Reviews Rheumatology</i> , 2017, 13, 386-386.	3.5	9
84	Identification and characterization of antigen-specific CD4+ T cells targeting renally expressed antigens in human lupus nephritis with two independent methods. <i>Scientific Reports</i> , 2020, 10, 21312.	1.6	9
85	Loss of balance in normal GPCR-mediated cell trafficking. <i>Frontiers in Bioscience - Landmark</i> , 2019, 24, 18-34.	3.0	9
86	Functional autoantibodies directed against cell surface receptors in systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 160-168.	1.0	8
87	Induction of Hypergammaglobulinemia and Autoantibodies by Salmonella Infection in MyD88-Deficient Mice. <i>Frontiers in Immunology</i> , 2018, 9, 1384.	2.2	8
88	<p></p>Serum Levels of Autoantibodies Against Extracellular Antigens and Neutrophil Granule Proteins Increase in Patients with COPD Compared to Non-COPD Smokers</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 189-200.	0.9	8
89	Autoantibodies Targeting AT1- and ETA-Receptors Link Endothelial Proliferation and Coagulation via Ets-1 Transcription Factor. <i>International Journal of Molecular Sciences</i> , 2022, 23, 244.	1.8	8
90	Editorial: Precision Medicine in Chronic Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 770462.	2.2	7

#	ARTICLE	IF	CITATIONS
91	Decreased endothelin receptor A autoantibody levels are associated with early ischaemic events in patients with giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1443-1444.	0.5	5
92	Immunoglobulin G of systemic sclerosis patients programs a pro-inflammatory and profibrotic phenotype in monocyte-like THP-1 cells. <i>Rheumatology</i> , 2020, 60, 3012-3022.	0.9	4
93	Autoantibodies against C5aR1, C3aR1, CXCR3, and CXCR4 are decreased in primary Sjogren's syndrome. <i>Molecular Immunology</i> , 2021, 131, 112-120.	1.0	4
94	Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database. <i>Rheumatology</i> , 2021, 61, 213-222.	0.9	4
95	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S31-5.	0.4	4
96	Diagnosis of deficiency of adenosine deaminase 2 with early onset polyarteritis nodosa in an adult patient with a novel compound heterozygous CECR1 mutation. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 177.	0.4	4
97	Effect of endothelin-1 receptor antagonists on skin fibrosis in scleroderma patients from the EUSTAR database. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 220-225.	1.0	3
98	Beta-1-Adrenergic Receptor Antibodies in Acute Coronary Syndrome: Is Less Sometimes More?. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 170.	1.1	3
99	Extracorporeal membrane oxygenation in ANCA-associated vasculitis. <i>Autoimmunity Reviews</i> , 2021, 20, 102702.	2.5	3
100	Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 68-75.	0.4	3
101	Autoimmunity to Sphingosine-1-Phosphate-Receptors in Systemic Sclerosis and Pulmonary Arterial Hypertension. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
102	Are we too lenient with immunosuppression in severe cases of Systemic Sclerosis?. <i>Rheumatology</i> , 2016, 55, 1914-1916.	0.9	2
103	Immunological changes and prevention of disease progression through elotuzumab therapy in refractory IgG4-related sclerosing mesenteritis. <i>Rheumatology</i> , 0, , .	0.9	2
104	Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101672.	1.4	1
105	Specific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years. <i>Journal of Personalized Medicine</i> , 2021, 11, 1207.	1.1	1
106	Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 114-121.	0.4	1
107	Detection of anti-neutrophil cytoplasmic and antinuclear autoantibodies favouring misdiagnoses in 5 cases of Erdheim-Chester disease. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 176.	0.4	1
108	Circulating CD4+CD8+ double-positive T-cells display features of innate and adaptive immune function in granulomatosis with polyangiitis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 93-98.	0.4	1



#	ARTICLE	IF	CITATIONS
109	Does angiotensin and endothelin receptor blockade have an impact on lung function? An analysis from the EUSTAR database. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 154-155.	0.4	1
110	SAT0021â€¦ELEVATED NUMBERS OF C-TYPE LECTIN CD161 POSITIVE PR3-SPECIFIC T-CELLS IN GPA. , 2019, , .		0
111	SAT0254â€¦VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY. , 2019, , .		0
112	Response to the Letter to the Editor: Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. <i>Archives of Rheumatology</i> , 2020, 35, 460-461.	0.3	0
113	Expansion of CD161 expressing CD8+ single-positive and CD4+CD8+ double-positive PR3-specific T-cells in granulomatosis with polyangiitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 182-183.	0.4	0
114	Expansion of CD161 expressing CD8+ single-positive and CD4+CD8+ double-positive PR3-specific T-cells in granulomatosis with polyangiitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 182-183.	0.4	0